Blood transfusion

Lore & Background

Blood transfusion involves transferring blood products into a person's circulation intravenously. Historically, doctors believed blood was homogeneous, leading to many patient deaths from incompatible transfusions. Modern practice uses components like red blood cells, plasma, and platelets, with whole blood reserved mainly for trauma settings. Red blood cells supply oxygen via hemoglobin; plasma is the yellowish liquid containing proteins; platelets aid clotting; white blood cells are rarely transfused.

Reader's Guide

Blood transfusion is a cornerstone of modern medicine, enabling treatment of anemia, trauma, clotting disorders, and other conditions. The shift from whole blood to component therapy has improved safety and efficiency, allowing targeted treatment. Compatibility testing—including ABO and Rh typing, antibody screening, and crossmatching—is critical to prevent adverse reactions. Leukoreduction and pathogen reduction technologies further reduce risks. Despite advances, transfusion carries risks, and guidelines now recommend more restrictive triggers (e.g., hemoglobin 70–80 g/L) to avoid unnecessary exposure. The World Health Organization recommends screening all donated blood for HIV, hepatitis B, hepatitis C, and syphilis, though some countries lack resources. Blood donation is motivated by altruism but hindered by fear and distrust. The field continues to evolve with better storage, testing, and processing methods.

Did You Know?

• Early doctors thought blood was homogeneous, leading to deaths from incompatible transfusions.
• Red blood cells are typically stored at 1–6 °C, platelets at 20–24 °C with agitation, and plasma frozen at −18 °C or lower.
• Leukoreduction removes white blood cells to reduce risks like febrile reactions and CMV transmission.
• Pathogen reduction using riboflavin and UV light can inactivate viruses, bacteria, parasites, and white blood cells in blood products.

From Whole Blood to Precision Components

Early transfusion practice relied on transferring whole blood directly into a patient's intravenous circulation. At the time, the medical community operated under the assumption that blood was a single, uniform substance. This misconception carried a terrible cost: numerous patients perished after receiving incompatible blood, simply because the distinct elements within it had not yet been identified. Modern medicine has moved far beyond that era. Today, clinicians typically transfuse only the specific component a patient needs—red blood cells to restore oxygen-carrying capacity, plasma to replenish proteins and buffering capacity, platelets to support clotting, or concentrated clotting factors for coagulation disorders. White blood cells are reserved for exceedingly rare situations, as granulocyte transfusion offers limited clinical benefit. Interestingly, whole blood has experienced a partial revival in the trauma setting, where rapid volume replacement takes priority over component separation. This evolution from a one-size-fits-all approach to targeted, component-specific therapy represents one of transfusion medicine's most significant advances.

Calibrating the Decision to Transfuse

Determining when and how much blood to give is a carefully calibrated clinical judgment. Evidence has since pushed that trigger lower, to roughly 70–80 g/L, because studies demonstrated that more conservative thresholds actually produce better patient outcomes. Administering larger volumes has been shown to worsen outcomes, which is why the one-and-recheck protocol is emphasized. Patients experiencing cardiovascular symptoms such as chest pain or dyspnea may warrant transfusion even at slightly higher levels. When anemia stems from iron deficiency and the patient is hemodynamically stable, oral or intravenous iron supplementation is generally preferred over transfusion on both efficacy and safety grounds. Fresh frozen plasma addresses clotting-factor deficiencies, while platelet products are reserved for thrombocytopenic patients at risk of bleeding.

The Global Pipeline from Donor to Patient

The journey of a blood unit from a donor's vein to a recipient's circulation involves multiple safeguards. In most high-income settings, donations are anonymous, yet every unit remains individually traceable through collection, testing, component separation, storage, and final administration—a chain that enables rapid investigation if a transfusion reaction or disease transmission is suspected. Blood is typically drawn intravenously as whole blood mixed with an anticoagulant, then separated by centrifugation into red cells, plasma, and platelets. Each component demands distinct storage: red cells at 1–6 °C, platelets at 20–24 °C under continuous agitation, and plasma frozen at −18 °C or below to preserve clotting factors. Plasma can be further fractionated into albumin, clotting-factor concentrates, cryoprecipitate, fibrinogen, and immunoglobulins. The WHO mandates screening for HIV, hepatitis B and C, syphilis, and, where relevant, Chagas disease and malaria; yet ten countries still lack the capacity to test for at least one of these core infections, largely because testing kits are unavailable. ABO and Rh compatibility testing is universal, and platelet products receive additional bacterial screening given their room-temperature storage.

Donation Culture and the Human Side of Safety

Behind every transfusion stands a donor, and the motivations driving that act are overwhelmingly prosocial—altruism, selflessness, and a desire to help others. Conversely, the principal deterrents are fear, institutional distrust, and, in some historical contexts, perceived racial discrimination in blood-collection practices. In developing regions, voluntary non-remunerated donation is less common; instead, replacement donors (family or friends of the recipient) and paid donors supply much of the blood, a pattern linked to concerns about infection transmission and local cultural beliefs. The question of whether an alcohol swab alone, or an alcohol swab followed by an antiseptic, best prevents donor-site contamination remains unresolved in the literature. For immunocompromised recipients—such as stem-cell transplant patients or individuals with T-cell disorders—donors may be screened for cytomegalovirus, though this is not universally mandated because leukoreduced products are generally considered safe from CMV transmission and most donors are already seropositive without active viremia. Allogeneic transfusion, using another person's blood, vastly outnumbers autologous self-donation procedures, making the integrity of the donor pool and the rigor of testing pipelines critical to public health.